



# Assessing Alzheimer's risk starts with a single blood test

## QUEST AD-Detect™ Amyloid Beta 42/40 Ratio is analytically validated and less invasive<sup>1,2</sup>

More than 6 million Americans are living with Alzheimer's—and that number is projected to more than double by 2050.<sup>3</sup> Combined with the increased burden of the COVID-19 pandemic on both patients and caregivers, assessing the risk of Alzheimer's disease has never been more critical.



### Assess Alzheimer's risk with a simple, accessible, and affordable blood test

QUEST AD-Detect gives you the diagnostic insights you need to assess the risk of Alzheimer's disease (AD). Our high-precision assay, using a simple blood sample, is the same type of assay shown to be as effective as traditional cerebrospinal fluid testing and amyloid positron emission tomography (PET) scans.<sup>4</sup> A more accessible and affordable option, plasma testing allows you to establish a baseline and monitor your patients through our 2,250+ Patient Service Center locations.



### Evaluate for Alzheimer's accurately and reliably with ratio of plasma Aβ42/40


QUEST AD-Detect assists in the differential diagnosis of AD.<sup>1,2</sup> QUEST AD-Detect is a high-precision assay of a type shown in a recently published study to be as effective as traditional methods.<sup>4</sup> Internal preliminary studies at Quest have shown the potential for QUEST AD-Detect to be as sensitive as a PET scan.<sup>1,2,4</sup>



### Inform potential treatment decisions

In addition to providing accessible insights into the risk of AD, QUEST AD-Detect blood-based biomarker testing may also help identify patients who are candidates for early antibody treatment.<sup>5</sup> As new therapies continue to emerge, antibody treatment may help slow disease progression and improve quality of life.

### QUEST AD-Detect Amyloid Beta 42/40 vs amyloid-PET status<sup>1,2</sup>






## Identify risk and monitor patients longitudinally

Our enhanced report provides A $\beta$ 42/40 ratio values from current and 5 past results in 1 table so you can continually monitor your patient's risk.

■ Lower risk of AD:  $\geq 0.160$

■ Higher risk of AD:  $< 0.160$

### QUEST AD-Detect, Amyloid Beta 42/40 Ratio, Plasma



## Ordering information

Test name	Specimen	Turnaround time	Test code
QUEST AD-Detect Amyloid Beta 42/40 Ratio	Plasma	3 -10 days	11786

## The power of Quest Advanced<sup>®</sup> Neurology

Innovative solutions, clinical expertise, and improved experiences for better patient outcomes.



**600+ medical experts** who are eager to consult with you on next steps for your patients



**Comprehensive insurer access**, serving more than 160 million patients annually



**Over 2,250 Patient Service Centers (PSCs)**, meeting patients where they live and work to ensure access to testing



**Quantum<sup>®</sup> Solutions**, a complete cloud EHR, helps keep practices efficient and patient-focused



**Our MyQuest<sup>™</sup> digital portal** gives your patients the ability to take charge of their personal health journey from any device



**Interface with over 600 EHR systems**—making sure you always have seamless access to ordering and results

Learn how Quest is actively working to end Alzheimer's at [QuestForTheCure.com](https://QuestForTheCure.com)

#### References:

1. Data on file. Quest Diagnostics; 2022.
2. Burnham SC, Fandos N, Fowler C, et al. Longitudinal evaluation of the natural history of amyloid- $\beta$  in plasma and brain. *Brain Commun.* 2020;2(1):fcaa041. doi:10.1093/braincomms/fcaa041
3. Alzheimer's Association. 2021 Alzheimer's disease facts and figures. Accessed December 7, 2021. <https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf>
4. Li Y, Schindler SE, Bollinger J, et al. Validation of plasma amyloid- $\beta$  42/40 for detecting alzheimer disease amyloid plaques. *Neurology*. Online ahead of print, December 14, 2021. doi:10.1212/WNL.00000000000013211
5. Cummings J, Lee G, Zhong K, et al. Alzheimer's disease drug development pipeline: 2021. *Alzheimers Dement (N Y)*. 2021;7(1):e12179. doi:10.1002/trc2.12179

Image content features a model and is intended for illustrative purposes only.

Test codes may vary by location. Please contact your local laboratory for more information.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—<sup>®</sup> and <sup>™</sup>—are the property of their respective owners. © 2022 Quest Diagnostics Incorporated. All rights reserved. SB10938 3/2022